Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Infinity Pharmaceuti (INFI)

Infinity Pharmaceuti (INFI)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Infinity to Present at The Keystone Symposia Precision Oncology Meeting

Infinity Pharmaceuticals, Inc. (NASDAQ: INFI), a clinical-stage biotechnology company developing eganelisib, a potentially first-in-class, oral, immuno-oncology macrophage reprogramming therapeutic which...

INFI : 3.33 (+2.78%)
Infinity Pharmaceuticals (INFI) Reports Q1 Loss, Tops Revenue Estimates

Infinity (INFI) delivered earnings and revenue surprises of -7.14% and 0.86%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

INFI : 3.33 (+2.78%)
Infinity: Q1 Earnings Snapshot

CAMBRIDGE, Mass. (AP) _ Infinity Pharmaceuticals Inc. (INFI) on Thursday reported a loss of $11.6 million in its first quarter.

INFI : 3.33 (+2.78%)
Infinity Pharmaceuticals Reports First Quarter 2021 Financial Results and Provides Company Update

---Update for eganelisib in PD-L1 low, 2L advanced UC patients expected mid-year-

INFI : 3.33 (+2.78%)
Infinity Pharmaceuticals, Inc. to Host Earnings Call

NEW YORK, NY / ACCESSWIRE / May 13, 2021 / Infinity Pharmaceuticals, Inc. (NASDAQ:INFI) will be discussing their earnings results in their 2021 First Quarter Earnings call to be held on May 13, 2021 at...

INFI : 3.33 (+2.78%)
Zoetis' (ZTS) Q1 Earnings and Revenues Surpass Estimates

Zoetis (ZTS) beat estimates for both earnings and revenues in the first quarter of 2021.

ZTS : 184.11 (-0.84%)
RGLS : 0.9200 (-1.27%)
INFI : 3.33 (+2.78%)
ONTX : 7.23 (+1.40%)
Infinity Announces the Date of Its First Quarter 2021 Financial Results Conference Call and Webcast

Infinity Pharmaceuticals, Inc. (NASDAQ: INFI), a clinical-stage biotechnology company developing eganelisib, a potentially first-in-class, oral, immuno-oncology macrophage reprogramming therapeutic that...

INFI : 3.33 (+2.78%)
Infinity to Present at New York Academy of Sciences' Frontiers in Cancer Immunotherapy 2021

Infinity Pharmaceuticals, Inc. (NASDAQ: INFI), a clinical-stage biotechnology company developing eganelisib, a potentially first-in-class, oral, immuno-oncology macrophage reprogramming therapeutic that...

INFI : 3.33 (+2.78%)
Pacira's (PCRX) Q1 Earnings Lag Estimates, Revenues Beat

Pacira's (PCRX) earnings in the first quarter of 2021 miss estimates while revenues beat the same. Exparel sales rise year over year.

IRWD : 11.47 (+2.59%)
PCRX : 60.82 (+1.91%)
CORT : 22.82 (+4.06%)
INFI : 3.33 (+2.78%)
Infinity Pharmaceuticals (INFI) May Report Negative Earnings: Know the Trend Ahead of Q1 Release

Infinity (INFI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

INFI : 3.33 (+2.78%)
Infinity to Present at the 7th Annual Truist Securities Life Sciences Summit

Infinity Pharmaceuticals, Inc. (NASDAQ: INFI), a clinical-stage biotechnology company developing eganelisib, a potentially first-in-class, oral, immuno-oncology macrophage reprogramming therapeutic which...

INFI : 3.33 (+2.78%)
FibroGen (FGEN) DMD Drug Pamrevlumab Gets FDA's Fast Track Tag

The FDA bestows a Fast Track designation to FibroGen's (FGEN) anti-CTGF antibody, pamrevlumab, to treat patients with Duchenne muscular dystrophy. Shares up.

ZTS : 184.11 (-0.84%)
INFI : 3.33 (+2.78%)
FGEN : 25.84 (+1.81%)
CTLT : 107.79 (-0.63%)
Thinking about buying stock in electroCore, Hall of Fame Resort & Entertainment, Dolphin Entertainment, Alithya Group, or Infinity Pharmaceuticals?

, /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for ECOR, HOFV, DLPN, ALYA, and INFI.

ALYA : 2.60 (-1.14%)
DLPN : 8.87 (+2.66%)
ECOR : 1.6600 (-3.49%)
HOFV : 4.52 (+3.91%)
INFI : 3.33 (+2.78%)
Thinking about buying stock in SuperCom, Clovis Oncology, Mogo Inc, Evolus, or Infinity Pharmaceuticals?

, /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for SPCB, CLVS, MOGO, EOLS, and INFI.

MOGO : 7.44 (-2.87%)
CLVS : 5.91 (+2.43%)
EOLS : 11.86 (unch)
INFI : 3.33 (+2.78%)
SPCB : 1.3800 (-2.82%)
Is the Options Market Predicting a Spike in Infinity (INFI) Stock?

Investors need to pay close attention to Infinity (INFI) stock based on the movements in the options market lately.

INFI : 3.33 (+2.78%)
Thinking about buying stock in Can Fite Biopharma, Aytu Bioscience, Hall of Fame Resort & Entertainment, Brickell Biotech, or Infinity Pharmaceuticals?

, /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for CANF, AYTU, HOFV, BBI, and INFI.

CANF : 2.41 (-2.82%)
BBI : 0.8592 (+0.20%)
HOFV : 4.52 (+3.91%)
INFI : 3.33 (+2.78%)
Infinity Pharmaceuticals (INFI) Reports Q4 Loss, Tops Revenue Estimates

Infinity (INFI) delivered earnings and revenue surprises of -6.25% and 11.80%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?

INFI : 3.33 (+2.78%)
Infinity: Q4 Earnings Snapshot

CAMBRIDGE, Mass. (AP) _ Infinity Pharmaceuticals Inc. (INFI) on Tuesday reported a loss of $10.6 million in its fourth quarter.

INFI : 3.33 (+2.78%)
Infinity: Q4 Earnings Snapshot

CAMBRIDGE, Mass. (AP) _ Infinity Pharmaceuticals Inc. (INFI) on Tuesday reported a loss of $10.6 million in its fourth quarter.

INFI : 3.33 (+2.78%)
Infinity Pharmaceuticals Reports Full Year 2020 Financial Results and Provides Update on Eganelisib Development

--- MARIO-3 initial data at SABCS demonstrate tumor reduction in 100% of patients and an ORR of 69.2%, irrespective of PD-L1 status, in 1L TNBC patients; updates in 1H '21 and 2H '21 -

INFI : 3.33 (+2.78%)

Barchart Exclusives

Meats In The Heart Of The 2021 Grilling Season
Lean hog futures had been outperforming cattle, making beef futures inexpensive compared to pork futures. Over the past week, cattle have rebounded, and hogs have retreated from the highest price since 2014. Read more

Barchart Futures Commentary

Barchart Futures is a twice weekly newsletter that features a selection of the latest and best commodities commentary appearing on Barchart.com. Delivered every Wednesday and Friday morning to your inbox.

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar